Pharmalot… Pharmalittle… Good Morning
Make a commentBy Ed Silverman // September 14th, 2010 // 6:49 am
Top of the morning to you. We are scurrying about in hopes of depositing one of the short people at the local schoolhouse. As always, this requires fortitude and a cup of stimulation. Meanwhile, we would like to remind you that we will host a webinar today (see this) with former US Attorney Mike Loucks about brand promotion compliance. And now, let the day begin. Have a good one, everyone…
Forest Labs Responds To FDA For COPD Drug (Pharma Times)
Pfizer Sees A Turnaround For Its Labs (Reuters)
Sanofi May Boost Genzyme Bid As Lab Unit Is Sold (Bloomberg News)
Counterfeit Drug Tally Is Hard To Swallow (Wall Street Journal)
Crestor Cuts Pneumonia Risk: Study (Bloomberg News)
Leave a Comment
Subscribe
Comments feed for this post only.
Tags
AstraZeneca, Chronic Obstructive Pulmonary Disease, COPD, Counterfeit Medicines, Crestor, Daxas, Forest Laboratories, Genzyme, Gilead Sciences, HIV, Pfizer, Pneumonia, Sanofi Aventis